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At 15' a f t e r injection, blcod l e v e l s were lower i n NB than i n children, but increased rapid1 and were high a t h s loo leve l s with CM a r e adequate and {isher and ~rolonoe!
d. !t a~-pears t o be safe and e f f e c t i v e i n the treatmeni o f ~N i n d UTI.' The data should encourage further evaluation o f the e f f i c a c y and hepatic and renal t o x i c i t i e s i n NB.
PROPRANOLOL ADMINISTRATION I N INFANCY. Carol M.
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Noonan. University of Kentucky College of Medicine.
Department of P e d i a t r i c s . Lexington, Kentucky.
Propranolol, (P) t h e b e t a blocking agent has been used f o r treatment of arrhythmia and hypercyanotic s p e l l s i n infancy. Very l i t t l e firm d a t a about pharmacologic parameters i s a v a i la b l e . This s e r i e s involves P l e v e l s i n 6 i n f a n t s . One i n f a n t , born t o a mother t r e a t e d with 160 mg Plday had P l e v e l s which increased over t h e f i r s t 4 h r s . of l i f e . Two newborns with a t r i a l arrhythmia r e f r a c t o r y t o Digoxin were begun on small doses of P which were increased u n t i l a t h e r a p e u t i c r e s u l t was obtained ( a t a dose of 1 mglkgl24 h r . ) .
Three i n f a n t s ranging i n age from 7-11 mos. (wgt.7-9 kg.) were t r e a t e d with 2.5 mgl kg124 h r . i n 4 divided o r a l doses f o r hypercyanotic s p e l l s . S e r i a l (P) l e v e l s were obtained from 45 min. t o 6 h r s . followi n g t h e o r a l dose and t h e s e l e v e l s were incorporated i n t o a curve from which t h e h a l f -l i f e (2.3 h r s . ) , t h e elimination. constant (0.005 min.-1) and t h e volume of d i s t r i b u t i o n (8.13LI kg) of t h e drug were c a l c u l a t e d . The P l e v e l decrease with r e s p e c t t o time was a s t r a i g h t l i n e function which yielded a c o r r e l a t i o n c o e f f i c i e n t of 0.93. These values a r e i d e n t i c a l with those from pharmacokinetic s t u d i e s i n a d u l t s . Conclusions:
(1) I n f a n t s > 7 mos.; > 7 kg. on 2.5 mglkgl24 h r . metabolize, d i s t r i b u t e , and e l i m i n a t e P a s a d u l t s . (2) I n t h e neonate, t h e s e v a l u e s may not apply and a dose of 1 mglkgl24 h r . was t h e r a p e u t i c . (3) Given t o pregnant women, t h e drug i s s t o r e d i n t h e f e t a l l i v e r and t h e increased l e v e l r e f l e c t s t h e i n a b i li t y of t h e f e t u s t o adequately metabolize t h e drug. Noting a geographical c l u s t e r i n g of Reye's syndrome i n a fore s t i n s e c t i c i d e spray a r e a . a seasonal study of plasma (PChE) and red c e l l c h o l i n e s t e r a s e (AChE) l e v e l s i n c h i l d r e n l i v i n g contiguous t o t h e f o r e s t spray a r e a has been c a r r i e d o u t . PChE and AChE a r e standard i n d i c e s f o r t h e t o x i c o l o g i c a l e f f e c t of organophosphate and carbarnate i n s e c t i c i d e s . S e r i a l samples of heparinized blood were c o l l e c t e d i n March. June and October from 100 c h i l d r e n and assayed f o r PChE and AChE, with t h e following r e s u l t s :
March PChE l e v e l s were s i g n i f i c a n t l y d i f f e r e n t between March and June (~( 0 . 0 1 ) with no s i g n i f i c a n t d i f f e r e n c e between June and October. AChE l e v e l s on t h e o t h e r hand do not vary s i g n i f i c a n t l y between March and June but a r e s i g n i f i c a n t l y higher i n October (pW0.001).
Forest spraying was done from May u n f i l June with an organophosphate, e m u l s i f i e r and s o l v e n t combination.
The depression of PChE during and a f t e r completion of t h e spraying program compared t o PChE l e v e l s i n t h e l a t e winter f u r n i s h e s biochemical evidence of chemical exposure t o i n s e c t ic i d e s i n a r e a s adjacent t o f o r e s t a r e a s suhjected t o l a r g e s c a l e spraying with i n s e c t i c i d e s . A s i m i l a r e f f e c t on AChE l e v e l s was
MAGNELIUM LEVELS I N INFANTS OF MOTHERS TREATED WITH
Coll. of PbS. Col. Univ., N.Y. Spona. by L.S. James MgS04 remains a coarmonly used therapy f o r o b s t e t r i c p a t i e n t s with pre-eclampsia o r premature l a b o r s b u t l i t t l e i s known of i t s e f f e c t s on t h e newborn. W e studied plasma magnesium (Mg) l e v e l s and u r i n a r y e x c r e t i o n of ME durinn t h e f i r s t 7 days of l i f e i n ---16 premature and 5 f u l l term i n f a n t s of mothers t r e a t e d with Mg. C l i n i c a l symptanatology consisted of mild hypotonia i n 11 c a s e s and d i d not c o r r e l a t e with peak plasma l e v e l s . The maternal p l a sma Mg l e v e l a t d e l i v e r y was 4.2t0.28 mg/dl (MtSE) and t h e r a t i o of maternal t o u m b i l i c a l a r t e r y (UA) v a l u e s was 1.14. The i n f a n t s ' plasma Mg r o s e from 3.68t0.20 mgldl (UA) t o 4.2t0.17 mgldl a t 2 hrs. of age (heel s t i c k ) . Subsequent l e v e l s showed a l i n e a r p l a sma e l i m i n a t i o n with a c o r r e l a t i o n c o e f f i c i e n t of -0.9533. The plasma t% was 43.22 hrs. Levels d i d not r e a c h a normal range (1.5 -2.5 mg/dl) u n t i l approximately 1 week of ape. There were no s i nn i f i c a n t d i f f e r e n c e s i n e i t h e r peak plasma l e v e l s o r r a t e of elimi n a t i o n between t h e following subgroups: i n f a n t s of mothers 1 ) receiving a t o t a l of >50 gm v s <50 gm; 2)receiving MgS04 f o r >24 h r s v s <24 h r s ; 3 ) r e c e i v i n g Mg i n f u s i o n s a t a r a t e of >1.5 gmlhr v s <1.5 vmlhr: 4)with plaama Mu c o n c e n t r a t i o n s >4 mg/dl v s <4 mg/ d l ; 5)who had pre-eclampsia v s those t r e a t e d f o r premature l a b o r only; and 6)premature v s f u l l term i n f a n t s . Urinary c l e a r a n c e fMn/creatinine) v a r i e d widely and f a i l e d t o show any c o n s i s t e n t a s s o c i a t i o n w i t h e i t h e r plasma l e v e l o r p o s t n a t a l age. Thus Mg, i n t h e doses administered and a t t h e plasma c o n c e n t r a t i o n s a t t a i n e d , bas a prolonned tk, but does n o t e x e r t any major d e l et e r i o u s e f f e c t s on t h e newborn.
AEROSOLIZED GENTAMICIN I N CYSTIC FIBROSIS: Michele A.
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P e r s i s t e n t c o l o n i z a t i o n of t h e r e s p i r a t o r y t r a c t with ps. aerug. is a major problem i n c h i l d r e n with c y s t i c f i b r o s i s (CF).
Because gentamicin p e n e t r a t i o n of CF sputum is inadequate a f t e r p a r e n t e r a l a d m i n i s t r a t i o n , we undertook an i n v e s t i g a t i o n of t h e s a f e t y and e f f i c a c y of gentamicin a e r o s o l .
Nine CF c h i l d r e n (5F, 4M) ages 6-15 years with moderately severe d i s e a s e were s t u d i e d . Following b a s e l i n e pulmonary and microbial s t u d i e s , each c h i l d received 40 mg of gentamicin s u l f a t e by n e b u l i z a t i o n t h r e e times d a i l y f o r one week.
Gentamicin d i s p o s i t i o n and pulmonary function were s t u d i e d i n i t i a l l y and a t t h e end of t h e treatment program.
No adverse e f f e c t s from t h e treatment were observed. Peak sputum concentrations of gentamicin varied from 3.6 t o 18.5 mcglml a f t e r one dose t o 6.4 t o 33 mcglml a f t e r one week of therapy.
Peak blood concentrations ranged from 0 t o 0.35 mcglml i n i t i a l l y and were somewhat higher st t h e end of t h e treatment program.
Urinary concentrations were i n s i g n i f i c a n t . The mean clearance of gentamicin from t h e sputum was 51 mllminl1.73 m2
(6 p t s ) . Microhial s t u d i e s i n f i v e p a t i e n t s demonstrated a s t r i k i n g decrease i n pseudomonas colony counts.
No s t r a i n s developed r e s i s t a n c e t o gentamicin. Pulmonary f u n c t i o n t e s t s improved i n 5 p a t i e n t s , showed no change i n 3, and diminished i n 1, perhaps i n a s s o c i a t i o n with a c l i n i c a l U R I .
A l l t h e c h i l d r e n showed marked c l i n i c a l improvement.
These r e s u l t s provide a r a t i o n a l e f o r , and s t r o n g l y warrant, a c l i n i c a l t r i a l of aeroaolized gentamicin i n CF p a t i e n t s .
CHRONIC PHENOBARBITAL ADMINISTRATION DURING INFANCY:
2 6 4 EFFECTS UPON BRAIN DEVELOPMENT I N RATS. Jaime Diaz, Richard J. Schsin. University of C a l i f o r n i a . Depts. of Psychiatry, Neurology and P e d i a t r i c s , Los Angeles, CA 90024. Recent s t u d i e s i n our l a b o r a t o r y have revealed t h a t phenobarbit a l r e t a r d s e a r l y b r a i n growth. I n t h e s e experiments t h e e f f e c t of chronic phenobarbital a d m i n i s t r a t i o n upon b r a i n development was evaluated under i s o c a l o r i c c o n d i t i o n s of n u t r i e n t i n t a k e . Chronic i n t r a g a s t r i c cannulas were i n s t a l l e d i n 4 day o l d Wistar r a t pups. From day 5 through day 1 8 , t h e s e animals received d a i l y subcutaneous i n j e c t i o n s of 60mg/kg of phenobarbital (11-15) o r of t h e v e h i c l e alone (n-12). An i n i t i a l period of s e d a t i o n was observed which gradually disappeared throughout t h e course of t h e experiment. On day 19, t h e animals were weighed and s a c r i f i c e d . There were no s i g n i f i c a n t d i f f e r e n c e s i n body weights between phenobarbital t r e a t e d and c o n t r o l groups. There was a 12% reduct i o n i n b r a i n weight of t h e phenobarbital t r e a t e d animals compared t o c o n t r o l s (p c.001).
DNA. RNA, p r o t e i n , and c h o l e s t e r o l c o n t e n t s i n t h e experimental animals were s i g n i f i c a n t l y lowered i n cerebrum. The cerebellum o f t h e s e animals was a f f e c t e d t o a l e s s e r e x t e n t b u t a l s o e x h i b i t e d growth r e t a r d a t i o n . These data' i n d i c a t e t h a t chronic phenobarbital a d m i n i s t r a t i o n i n t h e preweanling r a t s e l e c t i v e l y r e t a r d s b r a i n development. not observed.
